PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

LYNK Pharmaceuticals Co. Ltd.

USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
10
Total patents granted
4
CPC technology areas
13.8
Avg claims per patent
-
5-year filing velocity

The verdict

LYNK holds 10 US patents across 4 technology areas, rank #26,743 of 50,000 tracked assignees.

#26,743
of 50,000 US assignees by volume
Top 28%
by Innovation Score (43.6/100)
13.8
avg claims per patent

Portfolio overview

LYNK Pharmaceuticals Co. Ltd. has been granted 10 US utility patents between 2023 and 2025, placing LYNK Pharmaceuticals Co. Ltd. at rank #26,743 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, LYNK Pharmaceuticals Co. Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, LYNK sits between Lumenpulse Group Inc. (10 patents, rank #26,739) and Lakeside Software, Llc (10 patents, rank #26,747) - the closest US assignees by grant volume. The composite Innovation Score of 43.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. LYNK Pharmaceuticals Co. Ltd.'s 13.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark LYNK Pharmaceuticals Co. Ltd. against peers pursuing similar technology classes.

Who files at LYNK's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows LYNK holds 10 patents at rank #26,743, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near LYNK

By rank, the assignees closest to #26,743 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in LYNK's primary technology class.

LYNK's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 202320242025 1
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
LYNK Pharmaceuticals Co. Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 1 10.0%
2024 8 80.0%
2025 1 10.0%

Which technologies does LYNK Pharmaceuticals Co. Ltd. patent most?

Top 4 of 4 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard

Where it ranks

Overall rank by patents

#26,743

Across all tracked assignees

Innovation Score

43.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does LYNK Pharmaceuticals Co. Ltd. hold?
LYNK Pharmaceuticals Co. Ltd. holds 10 US granted patents filed between 2023 and 2025, spanning 4 technology areas.
What is LYNK Pharmaceuticals Co. Ltd.'s Innovation Score?
LYNK Pharmaceuticals Co. Ltd. has an Innovation Score of 43.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does LYNK Pharmaceuticals Co. Ltd. focus on?
LYNK Pharmaceuticals Co. Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 10 patents. The company has filed patents in 4 CPC subclasses total.
Is LYNK Pharmaceuticals Co. Ltd.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for LYNK Pharmaceuticals Co. Ltd..
What does claim depth mean for LYNK Pharmaceuticals Co. Ltd.'s patents?
LYNK Pharmaceuticals Co. Ltd.'s patents average 13.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the LYNK Pharmaceuticals Co. Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

LYNK's 10 grants land it in the top 28% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - LYNK ranks #26,743 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.